The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Canagliflozin ameliorates renal oxidative stress and inflammation by stimulating AMPK-Akt-eNOS pathway in the isoprenaline-induced oxidative stress model
Open accessAbstract
Diabetes is a leading cause of chronic kidney disease, and the high prevalence of sympathetic nervous system (SNS) hyperactivity in diabetic patients makes them further susceptible to SNS-mediated oxidative stress and accelerated kidney damage. Here, we investigated if canagliflozin can reverse isoprenaline (ISO)-induced renal oxidative damage in rats, a model that mimics SNS overstimulation-induced organ injuries in humans. We found that ISO administration elevates renal oxidative stress markers including malondialdehyde (MDA), advanced protein oxidation product (APOP), myeloperoxidase (MPO) and nitric oxide (NO), while depleting levels of endogenous antioxidants such as catalase (CAT), superoxide dismutase (SOD) and glutathione (GSH). Strikingly, canagliflozin treatment of ISO-treated rats not only prevents elevation of oxidative stress markers but also rescues levels of depleted antioxidants. Our results also show that canagliflozin stimulates antioxidant/anti-inflammatory signaling pathways involving AMP-activated protein kinase (AMPK), Akt and eNOS, and inhibits iNOS and NADPH oxidase isoform 4 (NOX4), all of which are associated with oxidative stress and inflammation. Further, canagliflozin prevents ISO-induced apoptosis of kidney cells by inhibiting Bax protein upregulation and caspase-3 activation. Histological examination of kidney sections reveal that canagliflozin attenuates ISO-mediated increases in inflammatory cell infiltration, collagen deposition and fibrosis. Finally, consistent with these findings, canagliflozin treatment improves kidney function in ISO-treated rats, suggesting that the antioxidant effects may be clinically translatable.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Further evidence that SGLT2 inhibition exerts antioxidant effects has been shown in an animal study demonstrating that canagliflozin stimulates antioxidant pathways involving AMPK, Akt, and endothelial nitric oxide synthase (Hasan et al., 2020).”
From A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors (2021) · cites this paper as Hasan et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Jollow, D. J., Mitchell, J. R., ZAMPAGLIONE, N. G., & Gillette, J. R. (2008) · Pharmacology · doi:10.1159/000136485 · Cited by 3,291
Diabetic Kidney Disease: Challenges, Progress, and Possibilities
Alicic, R. Z., Rooney, M. T., & Tuttle, K. R. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11491116 · Cited by 2,898
Advanced oxidation protein products as a novel marker of oxidative stress in uremia
Witko‐Sarsat, V., Friedlander, M. A., Capeillère‐Blandin, C., Nguyen‐Khoa, T., Nguyen, A., Zingraff, J., Jungers, P., & Descamps‐Latscha, B. (1996) · Kidney International · doi:10.1038/ki.1996.186 · Cited by 2,000
Shibata, R., Sato, K., Pimentel, D. R., Takemura, Y., Kihara, S., Ohashi, K., Funahashi, T., Ouchi, N., & Walsh, K. (2005) · Nature Medicine · doi:10.1038/nm1295 · Cited by 982
The Autoxidation of Human Red Cell Lipids Induced by Hydrogen Peroxide
Stocks, J., & Dormandy, T. L. (1971) · British Journal of Haematology · doi:10.1111/j.1365-2141.1971.tb00790.x · Cited by 979
Fujio, Y., Nguyen, T. U., Wencker, D., Kitsis, R. N., & Walsh, K. (2000) · Circulation · doi:10.1161/01.cir.101.6.660 · Cited by 846
The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease
Remuzzi, G., Perico, N., Macia, M. L., & Ruggenenti, P. L. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.09911.x · Cited by 513
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
(2017) · New England Journal of Medicine · doi:10.1056/nejmc1712572 · Cited by 415
Tracey, W. R., Tse, J., & Carter, G. (1995) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24521-9 · Cited by 310
Cited by
Sorted by citations
Bhatti, J. S., Sehrawat, A., Mishra, J., Sidhu, I. S., Navik, U., Khullar, N., Kumar, S., Bhatti, G. K., & Reddy, P. H. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.03.019 · Cited by 753
Neuroprotective effect of SGLT2 inhibitors.
Pawlos, A., Broncel, M., Woźniak, E., & Gorzelak-Pabiś, P. (2021) · Molecules · doi:10.3390/molecules26237213 · Cited by 304
An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors
Salvatore, T., Galiero, R., Caturano, A., Rinaldi, L., Martino, A. D., Albanese, G., Salvo, J. D., Epifani, R., Marfella, R., Docimo, G., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073651 · Cited by 279
Winiarska, A., Knysak, M., Nabrdalik, K., Gumprecht, J., & Stompór, T. P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910822 · Cited by 198
A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors
Sen, T., & Heerspink, H. J. L. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.02.016 · Cited by 161
SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits
Preda, A., Montecucco, F., Carbone, F., Camici, G. G., Lüscher, T. F., Kraler, S. C., & Liberale, L. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae047 · Cited by 210
Emergence of SGLT2 Inhibitors as Powerful Antioxidants in Human Diseases
Tsai, K., Chen, Y., Chiou, T. T., Chu, T., Li, L., Ng, H., Lee, W., & Lee, C. (2021) · Antioxidants · doi:10.3390/antiox10081166 · Cited by 140
Therapeutic Advances in Diabetic Nephropathy
Sawaf, H., Thomas, G., Taliercio, J. J., Nakhoul, G., Vachharajani, T. J., & Mehdi, A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11020378 · Cited by 123
Hoong, C. W. S., & Chua, M. W. J. (2021) · Endocrinology · doi:10.1210/endocr/bqab079 · Cited by 112
Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms
Huang, K., Luo, X., Liao, B., Li, G., & Feng, J. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01816-5 · Cited by 117
Immunomodulatory Effects of SGLT2 Inhibitors—Targeting Inflammation and Oxidative Stress in Aging
Schönberger, E., Mihaljević, V., Steiner, K., Šarić, S., Kurevija, T., Majnarić, L. T., Bilić-Čurčić, I., & Canecki-Varžić, S. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20176671 · Cited by 87
Yan, Y., Li, M., Lin, J., Ji, Y., Wang, K., Yan, D., Shen, Y., Wang, W., Huang, Z., Jiang, H., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.947387 · Cited by 84
Gager, G. M., von Lewinski, D., Sourij, H., Jilma, B., Eyileten, C., Filipiak, K., Hülsmann, M., Kubica, J., Postula, M. A., & Siller-Matula, J. M. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112169 · Cited by 70
Guo, W., Cao, Y.-J., You, S.-Z., Wu, Q., Zhang, F., Han, J., Lv, X., Rao, P., Ai, L., & Ni, L. (2022) · Current Research in Food Science · doi:10.1016/j.crfs.2022.02.013 · Cited by 62
Lu, Y.-P., Zhang, Z., Wu, H., Fang, L.-J., Hu, B., Tang, C., Zhang, Y., Yin, L., Tang, D., Zheng, Z., et al. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03629-8 · Cited by 58
Yang, Q., Lang, Y., Yang, W., Yang, F., Yang, J., Wu, Y., Xiao, X., Qin, C., Zou, Y., Zhao, Y., et al. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110592 · Cited by 62
Soares, R. N., Ramirez‐Perez, F. I., Cabral-Amador, F. J., Morales‐Quinones, M., Foote, C. A., Ghiarone, T., Sharma, N., Power, G. J., Smith, J. A. H., Rector, R. S., et al. (2022) · GeroScience · doi:10.1007/s11357-022-00563-x · Cited by 58
Long, Q., Li, L., Yang, H., Yang, L., Yang, H., Zhu, Y., Tang, Y., Liu, C., & Yuan, J. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109024 · Cited by 57
Systemic and organ-specific anti-inflammatory effects of sodium-glucose cotransporter-2 inhibitors
Mashayekhi, M., Safa, B. I., Gonzalez, M. S. C., Kim, S. F., & Echouffo-Tcheugui, J. B. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.02.003 · Cited by 54
Althagafy, H. S., Ali, F. E. M., Hassanein, E. H. M., Mohammedsaleh, Z. M., El-Sayed, M. I. K., Atwa, A. M., Sayed, A. M. M., & Soubh, A. A. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176166 · Cited by 39
A Role for SGLT-2 Inhibitors in Treating Non-diabetic Chronic Kidney Disease
Vecchio, L. D., Beretta, A., Jovane, C., Peiti, S., & Genovesi, S. (2021) · Drugs · doi:10.1007/s40265-021-01573-3 · Cited by 37
Arab, H. H., Eid, A. H., Gad, A. M., Yahia, R., Mahmoud, A. M., & Kabel, A. M. (2021) · Food Science & Nutrition · doi:10.1002/fsn3.2277 · Cited by 34
Repurposing SGLT2 Inhibitors for Neurological Disorders: A Focus on the Autism Spectrum Disorder
Nakhal, M. M., Aburuz, S., Sadek, B. S., & Akour, A. A. (2022) · Molecules · doi:10.3390/molecules27217174 · Cited by 33
Khamies, S. M., El-Yamany, M. F., & Ibrahim, S. M. (2024) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-024-10140-y · Cited by 32
Chang, D., Li, X.-Q., Chen, M., & Zhao, M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.729334 · Cited by 32
Abdelmageed, M. E., & Abdelrahman, R. S. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121654 · Cited by 32
Lee, S.-S., & Yoo, Y. C. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103807 · Cited by 32
Hassanein, E. H. M., Saleh, F. M., Ali, F. E. M., Rashwan, E. K., Atwa, A. M., & El‐Ghafar, O. A. M. A. (2022) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2022.2143371 · Cited by 28
The Pathophysiological Basis of Diabetic Kidney Protection by Inhibition of SGLT2 and SGLT1
Oe, Y., & Vallon, V. (2022) · Kidney and Dialysis · doi:10.3390/kidneydial2020032 · Cited by 29
Chen, X., Wang, J., Lin, Y., Liu, Y., & Zhou, T. (2022) · Cells · doi:10.3390/cells11233913 · Cited by 28
Afşar, B., & Afşar, R. E. (2022) · Pharmacological Reports · doi:10.1007/s43440-022-00442-4 · Cited by 28
Pan, M., Deng, Y., Qiu, Y., Pi, D., Zheng, C., Liang, Z., Zhen, J., Fan, W. H., Song, Q., Pan, J., et al. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155712 · Cited by 26
El‐Dessouki, A. M., Kaml, M. E., & El-Yamany, M. F. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-03908-3 · Cited by 25
Hasan, A., & Hasan, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910842 · Cited by 24
Self-citationNakhal, M. M., Jayaprakash, P., Aburuz, S., Sadek, B. S., & Akour, A. A. (2023) · Pharmaceuticals · doi:10.3390/ph16050769 · Cited by 23
Avogaro, A., de Kreutzenberg, S. V., Morieri, M. L., Fadini, G. P., & Prato, S. D. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00247-9 · Cited by 22
Refaat, B., & El‐Boshy, M. (2022) · Experimental Biology and Medicine · doi:10.1177/15353702211073804 · Cited by 21
Canagliflozin Inhibits Human Endothelial Cell Inflammation through the Induction of Heme Oxygenase-1
Peyton, K. J., Behnammanesh, G., Durante, G. L., & Durante, W. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158777 · Cited by 21
Ali, F. E. M., Hassanein, E. H. M., El‐Ghafar, O. A. M. A., Rashwan, E. K., Saleh, F. M., & Atwa, A. M. (2023) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.23309 · Cited by 21
Castoldi, G., Carletti, R., Ippolito, S., Colzani, M., Pelucchi, S., Zerbini, G., Perseghin, G., Zatti, G., & Gioia, C. R. T. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310710 · Cited by 21
Han, X., Liu, J., Bai, Y., Hang, A., Lu, T., & Mao, C. (2021) · Journal of Functional Foods · doi:10.1016/j.jff.2021.104488 · Cited by 21
Canagliflozin protects against sepsis capillary leak syndrome by activating endothelial α1AMPK
Angé, M., Poortere, J. D., Ginion, A., Battault, S., Dechamps, M., Muccioli, G. G., Roumain, M., Morelle, J., Druart, S., Mathivet, T., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-93156-1 · Cited by 21
Hasan, A., Menon, S. N., Zerin, F., & Hasan, R. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e09503 · Cited by 20
Self-citationStanciu, G. D., Ababei, D. C., Solcan, C., Bild, V., Ciobîcă, A., Chiriac, S. I. B., Ciobanu, L., & Tamba, B.-I. (2023) · Pharmaceuticals · doi:10.3390/ph16111620 · Cited by 21
Li, R., Wu, D., Hu, J., Ba, Y., Ba, Y., Zou, L., & Hu, Y. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.117513 · Cited by 18
SGLT2 inhibitor dapagliflozin protects the kidney in a murine model of Balkan nephropathy
Oe, Y., Kim, Y. C., Sidorenko, V. S., Zhang, H., Kanoo, S., Lopez, N., Goodluck, H. A., Crespo‐Masip, M., & Vallon, V. (2023) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00228.2023 · Cited by 18
Wang, T., Jia, Z., An, C., Ren, P., Yang, Y., Wang, W., & Su, L. (2023) · Molecules · doi:10.3390/molecules28248003 · Cited by 19
Feng, B., Yang, F., Liu, J., Sun, Q., Meng, R., & Zhu, D. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108409 · Cited by 17
Elbaz, E. M., Darwish, A., Gad, A. M., Rahman, A. A. S. A., & Safwat, M. H. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175993 · Cited by 18
Rajab, B. S., Albukhari, T. A., Khan, A. A., Refaat, B., Almehmadi, S. J., Nasreldin, N., Elshopakey, G. E., & El‐Boshy, M. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/4212331 · Cited by 16
Rojas-Solé, C., Pinilla-González, V., Lillo‐Moya, J., González-Fernández, T., Saso, L., & Rodrigo, R. (2023) · Redox Report · doi:10.1080/13510002.2023.2289740 · Cited by 21
Hasan, A., Zerin, F., Menon, S. N., Alam, M. A., & Hasan, R. (2022) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2022.09.004 · Cited by 15
Self-citationWITHDRAWN: SGLT2i reduces renal injury by improving mitochondrial metabolism and biogenesis
Peng, X., Chen, S., Wang, Y., Jin, M., Mei, F., Bao, Y., Liao, X., Chen, Y., & Gong, W. J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101613 · Cited by 15
RetractedGholami, M., Coleman‐Fuller, N., Salehirad, M., Darbeheshti, S., & Motaghinejad, M. (2024) · International Journal of Preventive Medicine · doi:10.4103/ijpvm.ijpvm_5_23 · Cited by 14
Bishr, A., Atwa, A. M., El-Mokadem, B. M., & El-Din, M. N. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04017-x · Cited by 14
Protective Effects of 2-Methoxyestradiol on Acute Isoproterenol-Induced Cardiac Injury in Rats
Hareeri, R. H., Alam, A. M., Bagher, A. M., Alamoudi, A. J., Aldurdunji, M. M., Shaik, R. A., Eid, B. G., & Ashour, O. M. (2023) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2023.101787 · Cited by 14
Sodium glucose cotransporter-2 inhibitors and heart disease: Current perspectives
Mondal, S., Pramanik, S., Khare, V. R., Fernandez, C. J., & Pappachan, J. M. (2024) · World Journal of Cardiology · doi:10.4330/wjc.v16.i5.240 · Cited by 15
Huang, C., Wei, Z., Zheng, N., Yan, J., Zhang, J., Ye, X., & Zhao, W. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14618 · Cited by 15
Liu, H., Chen, W., Wan, S., Chen, Y., Fu, M., Wang, Z., Xiong, F., & Zhang, Y. (2023) · Molecular Biology Reports · doi:10.1007/s11033-023-08855-x · Cited by 14
Abdelrahman, A. M., Awad, A. S., & Abdel‐Rahman, E. M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13040956 · Cited by 11
Chisty, T. T. E., Sarif, S., Jahan, I., Ismail, I. N., Chowdhury, F. I., Siddiqua, S., Yasmin, T., Islam, M. N., Khan, F., Subhan, N., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e25057 · Cited by 11
Self-citationLondzin, P., Brudnowska, A., Kurkowska, K., Wilk, K., Olszewska, K., Ziembiński, Ł., Janas, A., Cegieła, U., & Folwarczna, J. (2022) · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · doi:10.1016/j.biopha.2022.113679 · Cited by 10
Castoldi, G., Carletti, R., Barzaghi, F., Meani, M., Zatti, G., Perseghin, G., Gioia, C. R. T. D., & Zerbini, G. (2024) · Pharmaceuticals · doi:10.3390/ph17030362 · Cited by 10
Patel, T., Zheng, H., & Patel, K. P. (2025) · Antioxidants · doi:10.3390/antiox14030336 · Cited by 10
Varzideh, F., Kansakar, U., Wilson, S., Jankauskas, S. S., & Santulli, G. (2024) · Cell Cycle · doi:10.1080/15384101.2025.2492423 · Cited by 10
Unveiling the podocyte-protective effect of sodium-glucose cotransporter-2 inhibitors
Jiang, B., Cheng, Z., Wang, D., Liu, F., Wang, J., Fu, H., & Mao, J. (2024) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.24.144 · Cited by 9
Bishr, A., El-Mokadem, B. M., & Gomaa, A. A. (2025) · Scientific Reports · doi:10.1038/s41598-024-82163-7 · Cited by 9
El‐Ashmawy, N. E., Al‐Ashmawy, G. M., Kamel, A. A., & Khedr, E. G. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.167666 · Cited by 9
Menon, S. N., Zerin, F., Ezewudo, E., Simon, N. P., Menon, S. N., Daniel, M. L., Green, A. J., Pandey, A., Mackay, C., Hafez, S. S., et al. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115683 · Cited by 9
Self-citationHewedy, W. A., Abdulmalek, S. A., Ghareeb, D. A., & Habiba, E. S. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02627-x · Cited by 9
Nabrdalik-Leśniak, D., Nabrdalik, K., Irlik, K., Janota, O., Kwiendacz, H., Szromek‐Białek, P., Maziarz, M., Stompór, T. P., Gumprecht, J., & Lip, G. Y. H. (2023) · Endokrynologia Polska · doi:10.5603/ep.a2023.0039 · Cited by 10
Samaha, M. M., Helal, M. G., El‐Sherbiny, M., Said, E., & Salem, H. A. (2022) · Antioxidants · doi:10.3390/antiox11040691 · Cited by 8
Pandey, A., Zerin, F., Menon, S. N., Tithi, T. I., Nguyen, K. P., Vo, T., Daniel, M. L., Hafez, S. S., Alam, M. A., & Hasan, R. (2022) · Scientific Reports · doi:10.1038/s41598-022-08877-8 · Cited by 7
Self-citationExploring the correlation between periodontal disease and serum biomarkers in haemodialysis patients
Basha, M. M., Alkadasi, B. A., Al-Hajri, M., Al‐Sharani, H. M., & Elayah, S. A. (2024) · BMC Oral Health · doi:10.1186/s12903-024-04826-1 · Cited by 7
Yang, L., & Lv, Y. (2026) · Journal of Tissue Engineering · doi:10.1177/20417314251410000 · Cited by 7
Dimitriadis, K. S., Pitsiori, D., Alexiou, P., Pyrpyris, N., Sakalidis, A., Beneki, E., Iliakis, P., Tatakis, F., Theofilis, P., Tsioufis, P., et al. (2024) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001644 · Cited by 8
Abdelsalam, H. M., Helal, M. G., & Abu‐Elsaad, N. (2022) · PubMed Central · doi:10.22038/ijbms.2022.67168.14727 · Cited by 5
Yang, C., Xiao, C., Zhai, X., Liu, J. Y., & Yu, M. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108652 · Cited by 5
Zerin, F., Hoque, N., Menon, S. N., Ezewudo, E., Simon, N. P., Sooreni, S., Shahid, M. S., Jones, M., Pandey, A., Gökçe, Y., et al. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.116970 · Cited by 5
Self-citationWang, J., Li, D., Ju, W., & Wang, H. (2022) · Journal of Vascular Diseases · doi:10.3390/jvd1010007 · Cited by 5
Abdel-Rahman, R. F., Alsugoor, M. H., Alsuhaymi, N., Fayed, H. M., Mahmoud, S. S., Ibrahim, F. A., & Elbaset, M. A. (2025) · Saudi Pharmaceutical Journal · doi:10.1007/s44446-025-00039-x · Cited by 4
Sodium-glucose Cotransporter 2 Inhibitors and Pathological Myocardial Hypertrophy
Gao, Z., Bao, J., Hu, Y., Tu, J., Ye, L., & Wang, L. (2023) · Current Drug Targets · doi:10.2174/1389450124666230907115831 · Cited by 4
Tang, H., Donahoo, W. T., DeKosky, S. T., Lee, Y. A., Kotecha, P., Svensson, M., Bian, J., & Guo, J. S. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70313 · Cited by 4
Yu, Y.-J., & Chien, W. (2025) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-025-02026-7 · Cited by 4
Hassan, F. E., El‐Mosallamy, A. E. M. K., Khalifa, M. M., Aljuaydi, S. H., Ali, M. E., Hosny, S. A., & Bastawy, N. (2024) · Microscopy Research and Technique · doi:10.1002/jemt.24665 · Cited by 4
Renoprotective effects of dapagliflozin in an iron overload non-diabetic rat model
Fırat, S. N., Kuşkonmaz, Ş. M., Çaydere, M., Şeneş, M., Hücümenoğlu, S., & Çulha, C. (2022) · Advances in Medical Sciences · doi:10.1016/j.advms.2022.08.001 · Cited by 4
Bishr, A., Atwa, A. M., El-Naggar, M. E., & El-Din, M. N. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3974361 · Cited by 4
Miao, Y., He, P., Wang, D.-Y., Yan, L., Cao, H., & Shao, F.-M. (2026) · World Journal of Diabetes · doi:10.4239/wjd.v17.i2.112867 · Cited by 3
Zaini, L. M., Kartasasmita, A., Gondhowiardjo, T. D., Syukri, M., & Lesmana, R. (2022) · Expert Review of Ophthalmology · doi:10.1080/17469899.2022.2111302 · Cited by 3
Ivabradine curbs isoproterenol-induced kidney fibrosis
Baka, T., Stanko, P., Repova, K., Aziriova, S., Krajcirovicova, K., Barta, A., Zórad, Š., & Šimko, F. (2023) · General Physiology and Biophysics · doi:10.4149/gpb_2022057 · Cited by 3
Londzin, P., Zych, M., Janas, A., Siudak, S., & Folwarczna, J. (2025) · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · doi:10.1016/j.biopha.2025.117912 · Cited by 3
Li, C., Ng, J. K., Chan, G. C., Fung, W. W., Chow, K., & Szeto, C. (2025) · BMC Nephrology · doi:10.1186/s12882-025-04677-0 · Cited by 2
Potential Role of SGLT2 Inhibitors in the Treatment and Prevention of Diabetic Cardiomyopathy
Nandave, M. (2024) · Springer eBooks · doi:10.1007/978-981-97-7568-2_5 · Cited by 2
Sodium-Glucose Cotransporter 2 Therapy for Acute Organ Dysfunction in Critically Ill Patients
Gómez, H., & Derde, L. P. G. (2024) · JAMA · doi:10.1001/jama.2024.10171 · Cited by 2
Irokosu, E. S., Oladoja, F. A., Olayemi, S. O., & Ishola, I. O. (2024) · Pharmacological Research - Reports · doi:10.1016/j.prerep.2024.100025 · Cited by 1
Hassan, F. E., Hassanien, M. M., Selmy, A., Mahmoud, L. M., Darwish, A., & Aldreny, B. A. (2026) · Frontiers in Physiology · doi:10.3389/fphys.2025.1752370 · Cited by 1
Inflammation as a therapeutic target to improve kidney and cardiovascular outcomes
Tuttle, K. R., Kanbay, M., Alicic, R. Z., Carrero, J. J., Çöpür, S., Navar, A. M., Neuen, B. L., Perkovic, V., Rossing, P. R., Marx, N., et al. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-026-01117-6 · Cited by 2
Mechanisms of SGLT2 inhibition in the kidney
Sen, T. (2023) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.659987622
Pan, M., Deng, Y., Liang, Z., Pi, D., Zheng, C., Zhen, J., Fan, W. H., Song, Q., Pan, J., Li, Y., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4674253
Lu, Y.-P., Zhang, Z., Wu, H., Fang, L.-J., Hu, B., Tang, C., Zhang, Y., Yin, L., Tang, D., Zheng, Z., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21117692
Metadata
- Authors
- Hasan, R., Lasker, S., Hasan, A., Zerin, F., Zamila, M., Parvez, F., Rahman, M. M., Khan, F., Subhan, N., & Alam, M. A.
- Affiliations
- Mercer University Health Sciences Center (US)
- North South University (BD)
- Corresponding author
- Hasan, Raquibul
- Alam, Md. Ashraful
- ORCID
- Venue
- Scientific Reports
- Published
- 2020-09-04
- Volume
- 10
- Issue
- 1
- Pages
- 14659-14659
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC7474058
- OpenAlex
- W3083174088
- Cited by
- 111
- References
- 42
- Citations by year
- 2026: 11 · 2025: 15 · 2024: 20 · 2023: 24 · 2022: 28 · 2021: 13
- FWCI
- 10.30
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Scientific Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Greater South Information System
- Funders
- Mercer University College of Pharmacy
- North South University
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Health Sciences › Medicine › Physiology (medical) › Nitric Oxide and Endothelin Effects
- Keywords
- canagliflozin, renal oxidative stress, renal inflammation, sympathetic hyperactivity, diabetic nephropathy, nitric oxide, NOX4, inducible nitric oxide synthase, apoptosis, Bax, caspase-3, renal fibrosis, antioxidant enzymes, SGLT2 inhibitors
- MeSH terms
- Canagliflozin, Animals, Anti-Inflammatory Agents, Antioxidants, Cells, Cultured, Disease Models, Animal, Epithelial Cells, Humans, Inflammation, Isoproterenol, Kidney Tubules, Male, Oxidative Stress, Rats, Long-Evans, Proto-Oncogene Proteins c-akt, Rats, Renal Insufficiency, Nitric Oxide Synthase Type III, AMP-Activated Protein Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review